Iovance Biotherapeutics develops cell therapies against cancer. Immune cells from a patient’s tumor are multiplied and returned to the patient. Its first product, Amtagvi for advanced melanoma, is approved in the US. As of Oct 16, 2026
Iovance is a biopharmaceutical company that develops and markets cell therapies against solid tumors. In central facilities, the company multiplies each patient’s own immune cells. It markets Proleukin and Amtagvi, which has accelerated approval in the United States and approval in Canada for adults with advanced melanoma after certain prior treatments, including an antibody directed against PD-1. Proleukin goes to wholesalers at home and abroad and to other customers, for example for Amtagvi treatment and research. The therapies are manufactured in its own center in Philadelphia; after all Amtagvi manufacturing was moved there, the contract with a contract manufacturer ended in the first quarter of 2026.
Automatically summarized from SEC annual report (10-K, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 17, 2026
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Was in the buy zone
The price was in the buy zone and is now back just above it.
As of: Close of the 4-hour candle Oct 27, 2026, 18:30 · Buy zone in the trade plan · An observation, not investment advice
Rule (4-hour candles) Zone valid since Oct 26, 2026 · unchanged since then Zone historyThe zone history shows since when a buy zone has applied, when it was adjusted and when the price touched or left it. Recording began on Oct 12, 2026, only runs forward and fills nothing in – older zones are marked “known at start of recording” or “already existing when added”.Example: New buy zone on Oct 14, no adjustment since → “zone valid since Oct 14, 2026 · unchanged since”.More in the Academy: Lesson buy zone and Fibonacci
Watcher Full history: every change of the buy zone with its date.
Weekly candles (1W) No active buy zone – the last one ended in the Week from Oct 19, 2026 · Buy zone no longer valid Zone historyThe zone history shows since when a buy zone has applied, when it was adjusted and when the price touched or left it. Recording began on Oct 12, 2026, only runs forward and fills nothing in – older zones are marked “known at start of recording” or “already existing when added”.Example: New buy zone on Oct 14, no adjustment since → “zone valid since Oct 14, 2026 · unchanged since”.More in the Academy: Lesson buy zone and Fibonacci
Watcher Full history: every change of the buy zone with its date.
Timeframe 1 week · As of Oct 23, 2026 · display only, the rule works on 4-hour candles
Elliott count: Combination (W-X-Y), Corrective pattern (upward), Y in progress (1 of 2 guidelines) · X = 16% of W; Y = 16% of W
Alternative (not drawn): Combination (W-X-Y-X-Z), Corrective pattern (upward), Z in progress (1 of 3 guidelines)
Note: Retracement at least 88.7% of A: flat possible (B in progress, type only with C).
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
No buy zone of the rule on this timeframe – the chart shows only the Elliott count from the completed weekly candles (recalculated every day). Not a recommendation, not investment advice. Without a buy zone there is no reference for percentages – so no value axis and no prices; measurements are ratios of wave lengths.
Timeframe 1 day · As of Oct 27, 2026 · display only, the rule works on 4-hour candles
Elliott count: Combination (W-X-Y), Corrective pattern (upward), Y in progress (1 of 2 guidelines) · X = 16% of W; Y = 16% of W
Alternative (not drawn): Combination (W-X-Y-X-Z), Corrective pattern (upward), Z in progress (1 of 3 guidelines)
Note: Retracement at least 88.7% of A: flat possible (B in progress, type only with C).
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
No buy zone of the rule on this timeframe – the chart shows only the Elliott count from the completed daily candles (recalculated every day). Not a recommendation, not investment advice. Without a buy zone there is no reference for percentages – so no value axis and no prices; measurements are ratios of wave lengths.
Timeframe 4 hours · As of Oct 27, 2026
Elliott count: Zigzag (A-B-C), Corrective pattern (upward), C in progress (2 of 2 guidelines) · B = 39% of A; C = 40% of A
Comparison: The rule treats the last rise as the possible start of an upward impulse (without checking its history and structure). The Elliott count reads it as the end of an upward correction (C).
Note: Retracement at least 88.7% of A: flat possible (B in progress, type only with C).
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
Automated analysis (rule-based): the rule calculates waves and Fibonacci levels from the completed 4-hour candles; the chart is recalculated every hour. Not investment advice. Axis and values: distance from the top of the buy zone in %, no prices.
On phones the drawing toolbar is hidden – drawing works better on a desktop.
Timeframe 1 hour · As of Oct 27, 2026 · display only, the rule works on 4-hour candles
Elliott count: Impulse, Impulse pattern (downward), Wave 2 in progress (3 of 3 guidelines) · W2 = 72% of W1
Alternative (not drawn): Flat (type known only after C), Corrective pattern (upward), C in progress (2 of 2 guidelines)
Note: Structure ambiguous: leg W1 can also be read as three- or five-part.
Elliott count calculated automatically by fixed Elliott rules, not investment advice – display only, our buy zones do not use it. Provisional: The count can change with new candles.
Automated analysis (rule-based): the rule calculates waves and Fibonacci levels from the completed hourly candles; the chart is recalculated every hour. Not investment advice. On this timeframe the chart only shows the rule setup (swing detection 4 × ATR) – the rule itself works on 4-hour candles. Axis and values: distance from the top of the buy zone in %, no prices.
On phones the drawing toolbar is hidden – drawing works better on a desktop.
Timeframe 1 week · As of Oct 23, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario: ahead (1 of 2 guidelines, medium) · Alternative: behind (1 of 3, weak) Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
As long as the weekly close stays above the end of X, this applies: complex countermove upward (Combination W-X-Y), Y in progress – count points to rising prices.
Invalid if the weekly close is below the end of X
If that breaks, the second reading no longer applies either: complex countermove upward (Combination W-X-Y-X-Z), Z in progress – then there is no valid count for now; the next candles will produce a new one.
Invalid if the weekly close is below the end of the second X
Watcher Fibonacci target zones and levels for this count – as a help for your own review – from Watcher.
Timeframe 1 day · As of Oct 27, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario: ahead (1 of 2 guidelines, medium) · Alternative: behind (1 of 3, weak) Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
As long as the daily close stays above the end of X, this applies: complex countermove upward (Combination W-X-Y), Y in progress – count points to rising prices.
Invalid if the daily close is below the end of X
If that breaks, the second reading no longer applies either: complex countermove upward (Combination W-X-Y-X-Z), Z in progress – then there is no valid count for now; the next candles will produce a new one.
Invalid if the daily close is below the end of the second X
Watcher Fibonacci target zones and levels for this count – as a help for your own review – from Watcher.
Timeframe 4 hours · As of Oct 27, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario (2 of 2 guidelines, strong) · no alternative Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
As long as the 4-hour close stays above the end of B, this applies: sharp countermove upward in three waves (Zigzag A-B-C), C in progress – count points to rising prices.
Invalid if the 4-hour close is below the end of B (−8.6% from the top of the zone)
If that breaks, this count no longer applies. Currently no alternative that follows the rules.
Timeframe 1 hour · As of Oct 27, 2026 · from the Elliott count in the analysis chart
Weighting Main scenario: ahead (3 of 3 guidelines, strong) · Alternative: behind (2 of 2, strong) Guidelines (strength of the count)Guidelines are typical features of a count, such as usual Fibonacci lengths or a change in the form of correction. Strong means: at least three quarters met, medium: at least half, otherwise weak. Even a strong count can flip.Example: 3 of 3 guidelines → strong; 2 of 4 → medium; 1 of 3 → weak.More in the Academy: Lesson wave degrees
Weighting by guidelines met – not a probability.
As long as the hourly close stays below the start of wave 1, this applies: Downward move in five waves (Impulse), wave 2 in progress (pullback) – count then points to falling prices.
Invalid if the hourly close is above the start of wave 1 (+8.0% from the top of the zone)
If that breaks, the alternative moves to the front: flat countermove upward in three waves (Flat, type known only after C), C in progress – count points to rising prices, as long as the hourly close stays above the end of B.
Invalid if the hourly close is below the end of B (−6.3% from the top of the zone)
The price reached the buy zone (0 to −3.8% from its top) and last closed back above it. Rule trigger: after the touch a swing high forms, and a daily close is above it. If the price closes below the start of wave 1 (−8.6%), the setup is void. All percentages: distance from the top of the buy zone.
In the TradingView chart: Draw the buy zone in the chart with the Fibonacci tool (instructions next to the wave chart) or as two horizontal lines (tool “Horizontal Line”). If the price closes below the start of wave 1 (−8.6%), the setup is void – without an entry of the rule.
Exit with a gain
Buy zone – Rule trigger: candle close above the swing high
Exit at a loss
Watcher Target 1, Target 2 and stop for this zone – with distance in percent and reward/risk – are available from Watcher. Plans and pricing Percentages from the top of the buy zone (61.8%) – not a forecast.
Rule-based, long only, 4-hour candles. Not a forecast and not investment advice. Lesson: the buy zone in 4 minutes
Iovance Biotherapeutics · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 24, 2026.
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
34.3% Fiscal year 2025
Rank 25 of 100: higher than 25% of 153 peers (All). weak.
Rank 13 of 100: higher than 13% of 20 peers (Sector). weak.
Median Health Care: 66.6%
Share of revenue left after the direct cost of the products sold.
−153.1% Fiscal year 2025
Rank 7 of 100: higher than 7% of 192 peers (All). weak.
Rank 13 of 100: higher than 13% of 20 peers (Sector). weak.
Median Health Care: 18.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
−148.4% Fiscal year 2025
Rank 7 of 100: higher than 7% of 237 peers (All). weak.
Rank 6 of 100: higher than 6% of 26 peers (Sector). weak.
Median Health Care: 13.9%
Profit after all costs, interest and taxes divided by revenue.
−56.0% Fiscal year 2025
Rank 4 of 100: higher than 4% of 218 peers (All). weak.
Rank 2 of 100: higher than 2% of 21 peers (Sector). weak.
Median Health Care: 14.3%
Net income divided by equity at fiscal year end.
−42.8% Fiscal year 2025 (total assets at year end)
Rank 3 of 100: higher than 3% of 238 peers (All). weak.
Rank 6 of 100: higher than 6% of 26 peers (Sector). weak.
Median Health Care: 6.4%
Net income divided by total assets at fiscal year end.
76.5% Fiscal year 2025
Rank 93 of 100: higher than 93% of 239 peers (All). strong.
Rank 90 of 100: higher than 90% of 26 peers (Sector). strong.
Median Health Care: 38.5%
Equity as a share of total assets. Usually low for banks.
−127.6% Fiscal year 2025
Rank 7 of 100: higher than 7% of 213 peers (All). weak.
Rank 6 of 100: higher than 6% of 25 peers (Sector). weak.
Median Health Care: 14.9%
Free cash flow divided by revenue.
−336.2M USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
4 of 7 Fiscal year 2025
No rank: not all 9 criteria have data.
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
3.20 at fiscal year end
Rank 83 of 100: higher than 83% of 215 peers (All). strong.
Rank 83 of 100: higher than 83% of 26 peers (Sector). strong.
Median Health Care: 1.56
Current assets divided by current liabilities.
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 263.5M USD · Net income −391.0M USD · Net margin −148.4%
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Of 100 USD of revenue, 34.3 USD gross profit remained.
Operating loss: −153.1% of revenue
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 263.5M USD | 100.0% |
| Gross profit | 90.3M USD | 34.3% |
| Cost of revenue | 173.2M USD | 65.7% |
| Operating expenses | 493.7M USD | 187.4% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Return on equity fell in 5 years from −39.5% to −56.0%.
Return on equityReturn on assetsThe equity ratio fell in 5 years from 85.4% to 76.5%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.The current ratio fell in 5 years from 11.59 to 3.20.
Current ratioFree cash flow fell in 5 years from −251.9M USD to −336.2M USD.
Operating cash flowCapital expenditureFree cash flow in USDFrom annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Iovance Biotherapeutics next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| SYK Stryker Corporation | 25.1B USD | +11.8% | 64.0% | 19.5% | 12.9% | 14.5% | 46.9% | 17.1% | 6/9 |
| DHR Danaher Corporation | 24.6B USD | +2.0% | 59.1% | 19.1% | 14.7% | 6.9% | 62.9% | 21.4% | 7/9 |
| REGN Regeneron Pharmaceuticals | 14.3B USD | +11.0% | – | 24.9% | 31.4% | 14.4% | 77.1% | 28.4% | – |
| VRTX Vertex Pharmaceuticals | 12.0B USD | +14.1% | 86.2% | 34.8% | 32.9% | 21.2% | 72.8% | 26.6% | – |
| ISRG Intuitive Surgical | 10.1B USD | +18.2% | 66.0% | 29.3% | 28.4% | 16.0% | 87.1% | 24.7% | – |
| MRNA Moderna | 1.9B USD | +19.3% | 55.3% | −158.1% | −145.2% | −32.6% | 70.1% | −106.2% | 2/9 |
| NVAX Novavax | 1.1B USD | +18.8% | 93.5% | 40.3% | 39.2% | – | −10.9% | −22.3% | 5/9 |
| IOVA Iovance Biotherapeutics this stock | 263.5M USD | – | 34.3% | −153.1% | −148.4% | −56.0% | 76.5% | −127.6% | – |
| IBRX ImmunityBio | 113.3M USD | +299.7% | – | −226.0% | −310.2% | – | −99.7% | −272.6% | – |
| Median of the sector 26 symbols | 44.4B USD | +8.5% | 66.6% | 18.0% | 13.9% | 14.3% | 38.5% | 14.9% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
– per year, last 3 years
Sector Health Care: median +5.1% (62 symbols)
What does this mean? Reported annual figures for a comparison over at least 3 fiscal years are missing (or the SEC data has not been fully loaded yet).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
– per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
−148.4% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 148.38 USD.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
– latest balance sheet
Sector Health Care: median 0.66 (49 symbols)
What does this mean? No usable figure: reported financial debt or positive equity for the same balance sheet date is missing.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
– Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
0 of 10 fiscal years with a profit
What does this mean? In 0 of the last 10 fiscal years the bottom line showed a profit. 10 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 263.5M | −391.0M | −148.4% | −1.09 | – | – |
| 2024 | Dec 31, 2024 | 164.1M | −372.2M | −226.8% | −1.28 | – | – |
| 2023 | Dec 31, 2023 | 1.2M | −444.0M | −37,345.4% | −1.89 | – | – |
| 2022 | Dec 31, 2022 | – | −395.9M | – | −2.49 | – | – |
| 2021 | Dec 31, 2021 | – | −342.3M | – | −2.23 | – | – |
| 2020 | Dec 31, 2020 | – | −259.6M | – | −1.88 | – | – |
| 2019 | Dec 31, 2019 | – | −197.6M | – | −1.59 | – | – |
| 2018 | Dec 31, 2018 | 0.0 | −123.6M | – | – | – | – |
| 2017 | Dec 31, 2017 | 0.0 | −92.1M | – | – | – | – |
| 2016 | Dec 31, 2016 | 0.0 | −52.9M | – | – | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 99.3M | −47.3M | −47.6% | −0.11 | – | – |
| Q1/26 | Mar 31, 2026 | 71.4M | −79.0M | −110.7% | −0.19 | – | – |
| Q4/25* | Dec 31, 2025 | 86.8M | −71.9M | −82.9% | – | – | – |
| Q3/25 | Sep 30, 2025 | 67.5M | −91.3M | −135.3% | −0.25 | – | – |
| Q2/25 | Jun 30, 2025 | 60.0M | −111.7M | −186.2% | −0.33 | – | – |
| Q1/25 | Mar 31, 2025 | 49.3M | −116.2M | −235.5% | −0.36 | – | – |
| Q4/24* | Dec 31, 2024 | 73.7M | −78.6M | −106.6% | – | – | – |
| Q3/24 | Sep 30, 2024 | 58.6M | −83.5M | −142.7% | −0.28 | – | – |
| Q2/24 | Jun 30, 2024 | 31.1M | −97.1M | −312.2% | −0.34 | – | – |
| Q1/24 | Mar 31, 2024 | 715.0K | −113.0M | −15,800.8% | −0.42 | – | – |
| Q4/23* | Dec 31, 2023 | 482.0K | −116.4M | −24,145.0% | – | – | – |
| Q3/23 | Sep 30, 2023 | 469.0K | −113.8M | −24,255.9% | −0.46 | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
In the last 12 months, insiders of this stock have not acquired or disposed of shares on the market (SEC Form 4).
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
Latest news
No posts on IOVA yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules